Alignment Healthcare, Inc. (NASDAQ:ALHC - Get Free Report) CEO John E. Kao sold 90,000 shares of the stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $15.36, for a total value of $1,382,400.00. Following the transaction, the chief executive officer now directly owns 2,093,100 shares of the company's stock, valued at approximately $32,150,016. This trade represents a 4.12 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

NASDAQ ALHC traded down $0.21 during trading on Thursday, hitting $15.50. The company had a trading volume of 1,216,078 shares, compared to its average volume of 2,088,706. The company's fifty day moving average is $14.22 and its 200-day moving average is $12.34. The company has a current ratio of 1.60, a quick ratio of 1.60 and a debt-to-equity ratio of 1.82. The company has a market cap of $2.97 billion, a price-to-earnings ratio of -20.13 and a beta of 1.49. Alignment Healthcare, Inc. has a one year low of $4.46 and a one year high of $16.25.

Several institutional investors have recently made changes to their positions in ALHC. R Squared Ltd purchased a new stake in Alignment Healthcare in the fourth quarter worth $55,000. RiverPark Advisors LLC bought a new position in shares of Alignment Healthcare during the fourth quarter valued at approximately $106,000. Tower Research Capital LLC TRC raised its stake in Alignment Healthcare by 146.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 10,571 shares of the company's stock valued at $119,000 after buying an additional 6,286 shares during the last quarter. Ballentine Partners LLC purchased a new stake in Alignment Healthcare during the 4th quarter valued at about $121,000. Finally, Aigen Investment Management LP bought a new stake in shares of Alignment Healthcare during the fourth quarter valued at approximately $129,000. Institutional investors own 86.19% of the company's stock.

Several equities analysts have recently weighed in on the stock. William Blair reiterated an "outperform" rating on shares of Alignment Healthcare in a research note on Friday, February 28th. Barclays raised their price target on Alignment Healthcare from $8.00 to $9.00 and gave the company an "underweight" rating in a report on Friday, February 28th. JPMorgan Chase & Co. lifted their price objective on shares of Alignment Healthcare from $14.00 to $17.00 and gave the stock a "neutral" rating in a report on Thursday, March 6th. Stephens restated an "overweight" rating and issued a $17.00 target price on shares of Alignment Healthcare in a research report on Monday, February 24th. Finally, Bank of America upped their price target on shares of Alignment Healthcare from $15.50 to $18.50 and gave the company a "buy" rating in a research report on Tuesday, March 4th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $14.83.

Get Our Latest Stock Report on Alignment Healthcare

Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Before you consider Alignment Healthcare, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alignment Healthcare wasn't on the list.

While Alignment Healthcare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.